Solventum (SOLV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Solventum (SOLV) reported a revenue of $2 billion for the quarter ended December 2025, reflecting a decrease of 3.7% year-over-year, but exceeded the Zacks Consensus Estimate by 1.57% [1] - The company's EPS for the quarter was $1.57, an increase from $1.41 in the same quarter last year, surpassing the consensus estimate of $1.50 by 4.67% [1] Financial Performance - Net Sales in the MedSurg segment reached $1.24 billion, exceeding the average estimate of $1.21 billion, marking a year-over-year increase of 5.2% [4] - Health Information Systems reported Net Sales of $348 million, slightly below the average estimate of $350.75 million, with a year-over-year change of 3.6% [4] - Dental Solutions achieved Net Sales of $343 million, surpassing the estimated $327.99 million, representing an 8.9% increase compared to the previous year [4] Operating Income - MedSurg's Operating Income was reported at $191 million, below the average estimate of $212.55 million [4] - Health Information Systems had an Operating Income of $133 million, exceeding the average estimate of $121.94 million [4] - Dental Solutions reported an Operating Income of $84 million, above the average estimate of $78.05 million [4] Stock Performance - Over the past month, Solventum's shares have returned -2%, while the Zacks S&P 500 composite increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]